Completed PHASE2 INTERVENTIONAL 2-arm NCT01698476

Immune Reconstitution in Tuberculosis Disease (IRETB)

Immune Reconstitution in Tuberculosis Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate

Sponsor: Addis Ababa University

Interventions Placebo tablets vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)

Updated 5 times since 2017 Last updated: Feb 4, 2016 Started: Sep 30, 2012 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01698476, this PHASE2 trial focuses on Pulmonary Tuberculosis (TB) and remains completed. Sponsored by Addis Ababa University, it has been updated 5 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Addis Ababa University
Armauer Hansen Research Institute, Ethiopia
Karolinska Institutet

Data source: Karolinska Institutet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Addis Ababa, Ethiopia